|
|
|
|
| LEADER |
03321nam a2200349 u 4500 |
| 001 |
EB000943237 |
| 003 |
EBX01000000000000000736827 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
150223 r ||| eng |
| 245 |
0 |
0 |
|a New vaccinations
|h Elektronische Ressource
|b Lyme disease, rotavirus, hepatitis A, and pneumococcal disease
|c Minnesota Health Technology Advisory Committee
|
| 260 |
|
|
|a St. Paul
|b Minnesota Department of Health
|c 1999, 1999
|
| 300 |
|
|
|a 1 online resource
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Contraindications
|
| 653 |
|
|
|a Vaccines / therapeutic use
|
| 653 |
|
|
|a Risk Factors
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Adverse Drug Reaction Reporting Systems
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Vaccines
|
| 710 |
2 |
|
|a Minnesota
|b Health Technology Advisory Committee
|
| 710 |
2 |
|
|a Minnesota
|b Department of Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Minnesota health technology assessments
|
| 500 |
|
|
|a "Created: December 1999"
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK52500
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a For this reason, vigilance on the part of primary care physicians is and will remain a critical component of the efficacy and safety of vaccines. While the benefits of vaccination to society and the individual often outweigh any associated risks, continued clinical surveillance as well as ongoing research and development are essential to the minimization of existing risk
|
| 520 |
|
|
|a This report presents the clinical use of the new vaccines for Lyme disease, rotavirus, hepatitis A, and pneumococcal disease. The Lyme disease vaccine is not universally indicated. Instead, its use should be dependent upon individual risk factors, including both geographical and behavioral factors. The rotavirus vaccination (RotaShield), was initially universally indicated by the CDC's Advisory Committee on Immunization Practices. At present, the ACIP, after a review of scientific data, no longer recommends vaccination of infants in the United States and withdraws its recommendation that the RotaShield vaccine be administered at 2, 4, and 6 months of age. The hepatitis A vaccine is recommended by the ACIP for anyone more than two years of age desiring immunity and anyone in a high-risk group.
|
| 520 |
|
|
|a The pneumococcal disease vaccine is universally indicated for individuals over 65 years of age, and is recommended for those between the ages of 2 to 64 if they are immunocompromised, have a chronic illness, and/or live in a special environment such as a nursing home. The burden of pneumococcal disease is enormous in the United States. This vaccine is of particular importance in the current context of emerging drug-resistant strains of bacteria. Feed-back from the Centers for Disease Control and Prevention's (CDC) Vaccine Adverse Event Reporting System (VAERS) as well as continued emphasis on research into vaccine efficacy and safety are critical components to realizing the complete benefits of vaccination. Although vaccinations have been dubbed this century's greatest public health achievement, they are continually evolving into more safe and effective forms.
|